Fundraising Fox
Marengo Therapeutics
42 employees on LinkedIn · 1 known investors
Find your way into Marengo Therapeutics
Sign up to see every warm intro you have to Marengo Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Marengo Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Marengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.
Investors · 1
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Companies working in the same space as Marengo Therapeutics.
Frequently asked questions
- What does Marengo Therapeutics do?
- Marengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.
- Who are Marengo Therapeutics's investors?
- Marengo Therapeutics's investors include Scion Life Sciences.